NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Messaoudene, Meriem ^a   Fregni, Giulia ^b   Enot, David ^c   Jacquelot, Nicolas ^c,d   Neves, Emmanuelle ^a   Germaud, Nathalie ^e,f   Garchon, Henri Jean ^e,f   Boukouaci, Wahid ^a   Tamouza, Ryad ^a   Chanal, Johan ^g   Avril, Marie Françoise ^g,h   Toubert, Antoine ^a   Zitvogel, Laurence ^c,d,i,j   Rusakiewicz, Sylvie ^c   Caignard, Anne ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g Institut Cochin   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

more..

Author keywords

immunogenetics; melanoma; natural Killer cells; NK receptors

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; FOTEMUSTINE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEGRANULATION; DNA POLYMORPHISM; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 85007420337     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1154251     Document Type: Article

References (28)

1. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 1993; 91:1183-90; PMID:8450047; http://dx.doi.org/10.1172/JCI116278
2. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Liénard D, Gugerli O, Ferradini L, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004; 64:2192-8; PMID:15026362; http://dx.doi.org/10.1158/0008-5472.CAN-03-2969
3. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. NK cells:innate immunity against hematological malignancies? Trends Immunol 2004; 25:328-33; PMID:15145323; http://dx.doi.org/10.1016/j.it.2004.04.005
4. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 2014; 122:91-128; PMID:24507156; http://dx.doi.org/10.1016/B978-0-12-800267-4.00003-1
5. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
6. Moretta L, Moretta A. Unravelling natural killer cell function:triggering and inhibitory human NK receptors. EMBO J 2004; 23:255-9; PMID:14685277; http://dx.doi.org/10.1038/sj.emboj.7600019
7. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.smim.2006.03.002
8. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17:875-904; PMID:10358776; http://dx.doi.org/10.1146/annurev.immunol.17.1.875
9. Lopez-Botet M, Carretero M, Pérez-Villar J, Bellón T, Llano M, Navarro F. The CD94/NKG2 C-type lectin receptor complex. Curr Top Microbiol Immunol 1998; 230:41-52; PMID:9586349
10. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004; 16:626-33; PMID:15342010; http://dx.doi.org/10.1016/j.coi.2004.07.010
11. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
12. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499-510; PMID:23592754; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371
13. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra255; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
15. Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril MF, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013; 8:e76928; PMID:24204708; http://dx.doi.org/10.1371/journal.pone.0076928
16. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119(5):1251-63; PMID:19349689
17. Morgado S, Sanchez-Correa B, Casado JG, Duran E, Gayoso I, Labella F, Solana R, Tarazona R. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 2011; 3:365-73; PMID:21576932; http://dx.doi.org/10.1159/000328505
18. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816
19. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean MC, Alifano M, Régnard JF, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22; PMID:21708957; http://dx.doi.org/10.1158/0008-5472.CAN-10-4179
20. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-75; PMID:18203207; http://dx.doi.org/10.1002/cncr.23239
21. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases:influence of tumor origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847
22. Ruggeri L, Capanni M, Urbani E, Perrucio K, Shlomchik W, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natral killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2375-82; PMID:11896281; http://dx.doi.org/10.1126/science.1068440
23. Messaoudene M, Perier A, Fregni G, Neves E, Zitvogel L, Cremer I, Chanal J, Sastre-Garau X, Deschamps L, Marinho E, et al. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. PLoS One 2015; 10:e0133363; PMID:26218530; http://dx.doi.org/10.1371/journal.pone.0133363
24. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF, Caignard A. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011; 17:2628-37; PMID:21224372; http://dx.doi.org/10.1158/1078-0432.CCR-10-2084
25. Fregni G, Perier A, Avril MF, Caignard A. NK cells sense tumors, course of disease and treatments:Consequences for NK-based therapies. Onco Immunol 2012; 1:38-47; PMID:22720210; http://dx.doi.org/10.4161/onci.1.1.18312
26. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, Couturaud B, Girod A, Sastre-Garau X, Albert S, et al. Mature Cytotoxic CD56bright/CD16+ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. Cancer Res 2014; 74:81-92; PMID:24225017; http://dx.doi.org/10.1158/0008-5472.CAN-13-1303
27. Siewiera J, Gouilly J, Hocine HR, Cartron G, Levy C, Al-Daccak R, Jabrane-Ferrat N. Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nat Commun 2015; 6:10183; PMID:26666685; http://dx.doi.org/10.1038/ncomms10183
28. Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, et al. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunol in press.2016; PMID:1137418; http://dx.doi.org/10.1080/2162402X.2015.1137418